Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator

European Journal of Pharmaceutical Sciences

Volumn 44, Issue 3, 2011, Pages 265-272

  Jornil, Jakob ^a,c   Jensen, Klaus Gjervig ^b   Larsen, Frank ^b   Linnet, Kristian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Computer simulations; CYP2D6; Cytochrome P450; Nortriptyline; PBPK; Poisoning

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; NORTRIPTYLINE;

ARTICLE; BODY WEIGHT; DRUG INTOXICATION; DRUG METABOLISM; DRUG MONITORING; ELIMINATION REACTION; GENOTYPE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT;

ACCIDENTS; ADOLESCENT; ADULT; AGED; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; ISOENZYMES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NORTRIPTYLINE; RISK ASSESSMENT; YOUNG ADULT;

EID: 80053903085     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.08.003     Document Type: Article

References (78)

1. B. Alexanderson Pharmacokinetics of nortriptyline in man after single and multiple oral doses - predictability of steady-state plasma concentrations from single-dose plasma-level data Eur. J. Clin. Pharmacol. 4 1972 82 91
2. B. Alexanderson Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics - study in twins Eur. J. Clin. Pharmacol. 6 1973 44 53
3. B. Alexanderson, and O. Borga Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses Eur. J. Clin. Pharmacol. 5 1973 174 180
4. G. Alvan, O. Borga, M. Lind, L. Palmer, and B. Siwers First pass hydroxylation of nortriptyline - concentrations of parent drug and major metabolites in plasma Eur. J. Clin. Pharmacol. 11 1977 219 224 (Pubitemid 8072141)
5. I.M. Anderson Meta-analytical studies on new antidepressants Br. Med. Bull. 57 2001 161 178 (Pubitemid 32612677)
6. A. Avdeef Absorption and Drug Development: Solubility, Permeability, and Charge State 2003 John Wiley & Sons New Jersey
7. D.N. Bailey, and R.F. Shaw Interpretation of blood and tissue concentrations in fatal self-ingested overdose involving amitriptyline: an update (1978-1979) J. Anal. Toxicol. 4 1980 232 236 (Pubitemid 10021560)
8. C. Barbui, and M. Hotopf Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials Brit. J. Psychiat 178 2001 129 144 (Pubitemid 32158075)
9. P. Baumann, M. Jonzierperey, L. Koeb, P.K. Le, D. Tinguely, and J. Schopf Amitriptyline pharmacokinetics and clinical-response. 1. free and total plasma amitriptyline and nortriptyline Int. Clin. Psychopharm 1 1986 89 101
10. J.M. Bebchuk, and D.E. Stewart Drug-interaction between rifampin and nortriptyline - a case-report Int. J. Psychiatry. Med. 21 1991 183 187
11. L.Z. Benet A holy grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient Clin. Pharmacol. Ther. 86 2009 133 134
12. L. Bertilsson, M. Eichelbaum, B. Mellstrom, J. Sawe, H.U. Schulz, and F. Sjoqvist Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man Life Sci. 27 1980 1673 1677 (Pubitemid 11220225)
13. L. Bertilsson, B. Mellstrom, F. Sjokvist, B. Martenson, and M. Asberg Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications Lancet 1 1981 560 561 (Pubitemid 11130741)
14. L. Bertilsson, B. Mellstrom, and F. Sjoqvist Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriptyline Life Sci. 25 1979 1285 1292 (Pubitemid 10191650)
15. J.T. Biggs, D.G. Spiker, J.M. Petit, and V.E. Ziegler Tricyclic antidepressant overdose - incidence of symptoms JAMA 238 1977 135 138 (Pubitemid 8154914)
16. S.J. Billups, T. Delate, and D. Dugan Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations Pharmacoepidemiol. Drug Saf. 18 2009 253 257
17. L.D. Bradford CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 2002 229 243 (Pubitemid 34223859)
18. M. Brinkschulte, and U. BreyerPfaff Binding of tricyclic anti-depressants and perazine to human-plasma methodology and findings in normals Naunyn Schmiedebergs Arch. Pharmacol. 308 1979 1 7 (Pubitemid 10231485)
19. K. Brosen, and P. Kragh-Sorensen Concomitant intake of nortriptyline and carbamazepine Ther. Drug Monit. 15 1993 258 260 (Pubitemid 23171914)
20. J.E. Burch, S.G. Roberts, and M.A. Raddats Binding of amitriptyline and nortriptyline in plasma determined from their equilibrium distributions between red-cells and plasma and between red-cells and buffer solution Psychopharmacology 75 1981 262 272 (Pubitemid 12251777)
21. M.D. Cantu, S. Hillebrand, and E. Carrilho Determination of the dissociation constants (pKa) of secondary and tertiary amines in organic media by capillary electrophoresis and their role in the electrophoretic mobility order inversion J. Chromatogr. A 1068 2005 99 105 (Pubitemid 40568615)
22. M.L. Dahl, L. Bertilsson, and C. Nordin Steady state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype Psychopharmacology 123 1996 315 319 (Pubitemid 26075783)
23. P. Dalén, M.L. Dahl, M.L.B. Ruiz, J. Nordin, and L. Bertilsson 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes Clin. Pharmacol. Ther. 63 1998 444 452 (Pubitemid 28214968)
24. S. Dawling, K. Lynn, R. Rosser, and R. Braithwaite The Pharmacokinetics of nortriptyline in patients with chronic renal failure Br. J. Clin. Pharmacol. 12 1981 39 45 (Pubitemid 11082287)
25. H. Druid, P. Holmgren, B. Carlsson, and J. Ahlner Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results Forensic Sci. Int. 99 1999 25 34 (Pubitemid 29010322)
26. R.H. Gannon, and M.L. Anderson Fluconazole-nortriptyline drug-interaction Ann. Pharmacother. 26 1992 1456 1457
27. M. Gaviria, A.A. Gil, and J.I. Javaid Nortriptyline kinetics in hispanic and Anglo subjects J. Clin. Psychopharmacol. 6 1986 227 231 (Pubitemid 16004571)
28. L.F. Gram, P.B. Andreasen, K.F. Overo, and J. Christiansen Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man Psychopharmacology 50 1976 21 27
29. L.F. Gram, and K.F. Overø First-pass metabolism of nortriptyline in man Clin. Pharmacol. Ther. 18 1975 305 314
30. B.A. Howell, and A. Chauhan A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man J. Pharm. Sci. 99 2010 3601 3619
31. E.M. Howgate, K.R. Yeo, N.J. Proctor, G.T. Tucker, and A. Rostami-Hodjegan Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability Xenobiotica 36 2006 473 497 (Pubitemid 43890728)
32. M. Jamei, G.L. Dickinson, and A. Rostami-Hodjegan A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates Drug Metab. Pharmacokinet. 24 2009 53 75
33. M. Jerling, Y. Merle, F. Mentre, and A. Mallet Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum-likelihood method Br. J. Clin. Pharmacol. 38 1994 453 462 (Pubitemid 24344034)
34. J. Kirchheiner, K. Nickchen, M. Bauer, M.L. Wong, J. Licinio, I. Roots, and J. Brockmoeller Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol. Psychiatry 9 2004 442 473 (Pubitemid 38903502)
35. A. Koski, I. Ojanpera, J. Sistonen, E. Vuori, and A. Sajantila A fatal doxepin poisoning associated with a defective CYP2D6 genotype Am. J. Forensic Med. Pathol. 28 2007 259 261 (Pubitemid 47329748)
36. A. Koski, J. Sistonen, I. Ojanperae, M. Gergov, E. Vuori, and A. Sajantila CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies Forensic Sci. Int. 158 2006 177 183
37. S. Lee, C. Ki, K.S. Hong, and J.W. Kim A case report of a poor metaboliser of CYP2D6 presented with unusual responses to nortriptyline medication J. Korean Med. Sci. 19 2004 750 752 (Pubitemid 39452136)
38. H. Liedholm, and A. Liden Food intake and the presystemic metabolism of single doses of amitriptyline and nortriptyline Fundam. Clin. Pharmacol. 12 1998 636 642 (Pubitemid 29535488)
39. M.W. Linder, and P.E. Keck Standards of laboratory practice: antidepressant drug monitoring Clin. Chem. 44 1998 1073 1084 (Pubitemid 28213156)
40. K.P. Maguire, G.D. Burrows, T.R. Norman, and B.A. Scoggins Blood-plasma distribution ratios of psychotropic-drugs Clin. Chem. 26 1980 1624 1625
41. J.A. Mclure, J.O. Miners, and D.J. Birkett Nonspecific binding of drugs to human liver microsomes Br. J. Clin. Pharmacol. 49 2000 453 461 (Pubitemid 30229449)
42. B. Mellstrom, L. Bertilsson, J. Sawe, H.U. Schulz, and F. Sjoqvist E-10-hydroxylation and Z-10-hydroxylation of nortriptyline - relationship to polymorphic debrisoquine hydroxylation Clin. Pharmacol. Ther. 30 1981 189 193 (Pubitemid 11039356)
43. D.D. Miller, J.B. Sawyer, and J.P. Duffy Cimetidine's effect on steady-state serum nortriptyline concentrations Drug Intell. Clin. Pharm. 17 1983 904 905 (Pubitemid 15156005)
44. S. Morita, K. Shimoda, T. Someya, Y. Yoshimura, K. Kamijima, and N. Kato Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline J. Clin. Psychopharmacol. 20 2000 141 149 (Pubitemid 30202355)
45. C. Nordin, and L. Bertilsson Active hydroxymetabolites of antidepressants - emphasis on E-10-hydroxy-nortriptyline Clin. Pharmacokinet. 28 1995 26 40
46. G. Nyberg, and E. Martensson Determination of free fractions of tricyclic antidepressants Naunyn Schmiedebergs Arch. Pharmacol. 327 1984 260 265 (Pubitemid 14029009)
47. O.V. Olesen, and K. Linnet Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isoenzymes Drug. Metab. Dispos. 25 1997 740 744 (Pubitemid 27259974)
48. P.J. Orsulak Therapeutic monitoring of antidepressant drugs - guidelines updated Ther. Drug Monit. 11 1989 497 507 (Pubitemid 19232942)
49. K.F. Overo, L.F. Gram, and V. Hansen Kinetics of nortriptyline in man according to a 2 compartment model Eur. J. Clin. Pharmacol. 8 1975 343 347
50. M. Perera The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin. Drug Metab. Toxicol. 6 2010 17 28
51. P.J. Perry, C. Zeilmann, and S. Arndt Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response J. Clin. Psychopharmacol. 14 1994 230 240 (Pubitemid 24254714)
52. P. Petersen, and K. Brosen Severe nortriptyline poisoning in poor metabolizers of the sparteine type Ugeskr. Laeg. 153 1991 443 444
53. J.M. Petit, D.G. Spiker, J.F. Ruwitch, V.E. Ziegler, A.N. Weiss, and J.T. Biggs Tricyclic antidepressant plasma-levels and adverse-effects after overdose Clin. Pharmacol. Ther. 21 1977 47 51 (Pubitemid 8024159)
54. B.G. Pollock, G. Everett, and J.M. Perel Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites Neuropsychopharmacology 6 1992 1 10
55. R. Regenthal, M. Krueger, C. Koeppel, and R. Preiss Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs J. Clin. Monit. Comput. 15 1999 529 544 (Pubitemid 30311655)
56. M. Reis, T. Aamo, J. Ahlner, and H. Druid Reference concentrations of antidepressants: a compilation of postmortem and therapeutic levels J. Anal. Toxicol. 31 2007 254 264 (Pubitemid 46911622)
57. M. Reis, T. Aamo, O. Spigset, and J. Ahlner Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database Ther. Drug Monit. 31 2009 42 56
58. R.L. Roberts, R.T. Mulder, P.R. Joyce, S.E. Luty, and M.A. Kennedy No evidence of increased adverse drug reactions in cytochrome P450CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline Hum. Psychopharm. Clin. 19 2004 17 23 (Pubitemid 38159271)
59. D.E. Rollins, G. Alvan, L. Bertilsson, J.R. Gillette, B. Mellstroem, F. Sjoeqvist, and L. Traeskman Interindividual differences in amitriptyline demethylation Clin. Pharmacol. Ther. 28 1980 121 129
60. A. Rostami-Hodjegan, and G.T. Tucker Simulation and prediction of in vivo drug metabolism in human populations from in vitro data Nat. Rev. Drug Discov. 6 2007 140 148 (Pubitemid 46745341)
61. M. Rowland, C. Peck, and G. Tucker Physiologically-based pharmacokinetics in drug development and regulatory science Annu. Rev. Pharmacol. Toxicol. 10 2011 45 73
62. M. Schulz, and A. Schmoldt Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics Pharmazie 58 2003 447 474 (Pubitemid 36869876)
63. T. Self, C.R. Corley, S. Nabhan, and T. Abell Case report: interaction of rifampin and nortriptyline Am. J. Med. Sci. 311 1996 80 81 (Pubitemid 26055150)
64. J.R. Swanson, G.R. Jones, W. Krasselt, L.N. Denmark, and F. Ratti Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms J. Forensic Sci. 42 1997 335 339 (Pubitemid 27113504)
65. J.J. Swen, I. Wilting, A.L. de Goede, L. Grandia, H. Mulder, D.J. Touw, A. de Boer, J.M.H. Conemans, T.C.G. Egberts, O.H. Klungel, R. Koopmans, J. van der Weide, B. Wilffert, H.J. Guchelaar, and V.H.M. Deneer Pharmacogenetics: from bench to byte Clin. Pharmacol. Ther. 83 2008 781 787 (Pubitemid 351556025)
66. TIAFT (The International Association of Forensic Toxicologists), 2007. Reference blood level list of therapeutic and toxic substances. http://www.tiaft.org/tmembers/ttv/ttv-el.php. Accessed Jan 2010.
67. D. Tomalik-Scharte, D. Lutjohann, O. Doroshyenko, D. Frank, A. Jetter, and U. Fuhr Plasma 4 beta-hydroxycholesterol: an endogenous CYP3A metric? Clin. Pharmacol. Ther. 86 2009 147 153
68. K. Venkatakrishnan, L.L. Von Moltke, and D.J. Greenblatt Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 [high affinity] and CYP3A4 [low affinity]: implications for interactions with enzyme-inducing drugs J. Clin. Pharmacol. 39 1999 567 577 (Pubitemid 30629036)
69. C. von Bahr, E. Steiner, Y. Koike, and J. Gabrielsson Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism Clin. Pharmacol. Ther. 64 1998 18 26 (Pubitemid 28377326)
70. G.R. Wilkinson, and D.G. Shand Physiological approach to hepatic drug clearance Clin. Pharmacol. Ther. 18 1975 377 390
71. B.L. Williamson, S. Purkayastha, C.L. Hunter, L. Nuwaysir, J. Hill, L. Easterwood, and J. Hill Quantitative protein determination for CYP induction via LC-MS/MS Proteomics 11 2011 33 41
72. C.L. Winek, W.W. Wahba, C.L. Winek, and T.W. Balzer Drug, chemical blood-level data Forensic Sci. Int. 122 2001 107 123
73. J.S. Yang, M. Jamei, A. Heydari, K.R. Yeo, R. de la Torre, M. Farre, G.T. Tucker, and A. Rostami-Hodjegan Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA J. Psychopharmacol. 20 2006 842 849 (Pubitemid 44622750)
74. J.S. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr. Drug Metab. 8 2007 676 684 (Pubitemid 47578116)
75. K.R. Yeo, M. Jamei, J.S. Yang, G.T. Tucker, and A. Rostami-Hodjegan Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - The effect of diltiazem on the time-course of exposure to triazolam Eur. J. Pharm. Sci. 39 2010 298 309
76. Q.Y. Yue, Z.H. Zhong, G. Tybring, P. Dalén, M.L. Dahl, L. Bertilsson, and F. Sjoqvist Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes Clin. Pharmacol. Ther. 64 1998 384 390 (Pubitemid 28473764)
77. A.L. Zackrisson, P. Holmgren, A.B. Gladh, J. Ahlner, and B. Lindblom Fatal intoxication cases: cytochrome P 450 2D6 and 2C19 genotype distributions Eur. J. Clin. Pharmacol. 60 2004 547 552 (Pubitemid 39517906)
78. U.M. Zanger, S. Raimundo, and M. Eichelbaum Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch. Pharmacol. 369 2004 23 37 (Pubitemid 38161221)